Clear Cell Chondrosarcoma in Italy (CIRCLE)

January 14, 2026 updated by: Istituto Ortopedico Rizzoli

Clear Cell Chondrosarcoma in Italy: Insights Into Radiological, Clinical and pathologicaL Features, With Emphasis on Prognosis (CIRCLE)

Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Bologna, Italy, 40136
        • IRCC Rizzoli Orthopedic Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male and female patients with diagnosis of clear cell chondrosarcoma and chondrosarcoma with a clear cell component treated from 01 Jan 1982 to 31 Dec 2023
  • Information available (date of primary tumor diagnosis, local treatments, systemic treatment, response to systemic treatment, date of progression) and date and status at last follow-up
  • Imaging studies available for revision
  • Histological slides available for revision

Exclusion Criteria:

  • - Diagnosis different from clear cell chondrosarcoma or chondrosarcoma with a clear cell component;
  • Absence of radiological and/or clinical data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients
Patients with a diagnosis of clear cell chondrosarcoma
Genetic: Molecular studies
Molecolar studies to define possible prognostic parameters

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prognostic accuracy
Time Frame: At baseline
Ability of the model to predict overall survival, measured by AUC/C-index
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Ortopedico Rizzoli

Collaborators

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Azienda Ospedaliera Universitaria Pisana, Pisa
Gaetano Pini CTO, Milano
IRCCS Humanitas Research Hospital, Milano
Ospedale "Morgagni - Pierantoni" di Forlì
AOU Città della Salute e della Scienza Torino
Azienda Consorziale Ospedaliero-Universitaria Policlinico di Bari

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 10, 2025

Primary Completion (Actual)

December 31, 2025

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIRCLE

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chondrosarcoma

Clinical Trials on Molecular studies

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe